Video summary

2026卒試前補講 小児科 前半

Main summary

Key takeaways

Educational

Main ideas / lessons conveyed

1) How the 2026 pediatric exam is structured and what to focus on

  • The pediatrics exam covers a broad scope, divided into ~16 sub-areas.
  • For this year’s exam:
    • The overall system stays the same each year, but question creation is divided among people in minor science departments.
    • Many questions are new; only a small portion match or closely resemble past questions.
  • The lecturer states that the provided lecture slides cover >90% of the relevant exam material based on the lecturer’s own judgment/interpretation.
    • Recommendation: cross-check with official course/lecture materials as well.

2) “Walking” (exam prep) approach for pediatrics: split into two halves

  • The lecture is divided into:
    • First half
    • Second half
  • Each half contains about ~140 slides.
  • In the lecturer’s “walking” material:
    • Certain symbols from earlier lectures do not appear, implying that every slide matters.

Detailed content of the First Half (core medical topics)

A. Genetic predisposition / hereditary patterns (≥1000–type content)

  • Core concept: the “≥1000 points” category refers to predisposition—the disease cause is inborn/connected to the system.
    • This includes cases where symptoms may not appear immediately but are present from birth.
  • Important clarification:
    • A high score does not automatically mean a genetic disorder, because some lower categories are not genetic.

Single-gene mutation (top category)

  • Described as affecting the face, divided into two broad inheritance patterns:
    1. Autosomal dominant-like
      • If one allele carries an abnormal gene, disease can develop.
      • Even if one chromosome has a normal gene and the other has an abnormal gene, disease may still occur.
      • Recurrence example:
        • Patient × healthy parent → recurrence risk discussed as ~50%.
    2. Autosomal recessive
      • Disease develops only if both alleles are abnormal.
      • One abnormal + one normal allele → carrier, typically no disease.
      • Siblings affected is commonly described.
      • Two-carrier parents → child disease risk ~25%.

Sex-linked inheritance (X-linked)

  • “X-linked” concept described as:
    • If a normal allele is present on the relevant X, disease may not develop (women described as possible asymptomatic carriers).
    • Men described as more likely to manifest because they are XY.
  • Risk figures mentioned:
    • ~25% in one scenario (carrier × healthy parent)
    • ~50% when considering males only

Chromosomal abnormalities (≥1000-category group)

  • Frequencies/types mentioned:
    • Chromosome 21 most common (> half), then 18 and 13.
    • Down-type (trisomy 21) incidence stated as ~1 in 1000 births.
  • Maternal age relationship:
    • Incidence increases sharply after age 35.
    • Yet since most births occur under 35, ~80% of Down syndrome cases are from mothers under 35 (as stated).
  • Down syndrome complications:
    • Congenital complications described as common (~50%).
    • Digestive/system-related issues noted.
  • Circulatory conditions mentioned later:
    • AVSD (most frequent), followed by VSD-like and septal defects (discussed as part of circulation content).

Prenatal screening and confirmation

  • NIPT:
    • A blood test using maternal blood to detect fetal DNA.
    • Targets mainly trisomies 21/18/13.
  • Eligibility/timing:
    • Genetic predisposition assessed.
    • Blood sample around 10 weeks or later.
    • If needed, additional confirmatory testing (IVF-related tests were mentioned).
  • “Anticipation” concept:
    • Earlier onset and/or increased severity across generations.
    • Examples: Huntington-like and Fragile X mentioned (subtitles may be garbled).

B. Newborn asphyxia / brain injury concepts + cooling therapy (hypoxic-ischemic type ideas)

  • Discussed as arising from newborn transition issues:
    • Respiratory/circulatory failure → symptoms appear.
    • Resuscitation restores blood flow; behavioral and neural development issues described.
  • Mechanism:
    • Secondary nerve cell injury described as preventable with early treatment.
    • If treated later, secondary injury progresses and therapy becomes ineffective.

Cooling (“biotherapy”) treatment methodology

  • Target temperature: ~33–34°C
  • Duration:
    • Cool for 72 hours, then gradually rewarm/recover.
  • Selection criteria mentioned:
    • Gestational age: ≥36 weeks
    • Weight: ≥1800 g
    • Start time: within 6 hours after birth (effect decreases after that window)
    • Severity/eligibility:
      • Apgar ≤5 at 10 minutes
      • Blood gas: pH < 7.0 (threshold as stated)
      • Additional imaging severity threshold mentioned (wording unclear in subtitles)
  • Risks/limits:
    • Not for all cases; small/underweight babies may have risk outweighing benefits.
    • Effectiveness noted as not broadly proven (as framed in subtitles).

C. Neonatal injury types from procedures / trauma (“extra-text compensation” section)

  • Injury described as caused by external force applied during procedures.

  • Lecturer focuses on three types (names partially garbled in subtitles):

    1. “Third-tier” type (pressure-related; not bleeding)
      • Appears large at birth, disappears within ~23 days.
    2. “Blood” type (bleeding; location between bone and fascia described)
      • Grows over a few days, disappears over a few months.
    3. Protective barrier / membrane spread type
      • Bleeding risk with severe outcomes.
      • May worsen → severe anemia → hypovolemic shock or DIC risk.
      • Prevention emphasized as “life-threatening,” so it must be remembered.

D. Respiratory patterns in newborn injury (“C-breathing”)

  • A described breathing effort pattern:
    • Inhalation: chest/cornea lowers, abdomen expands but lungs don’t properly expand → stomach rises.
    • Exhalation: cornea rises, abdomen lowers → siphon-like effort pattern.
  • Framed as important for recognizing breathing effort patterns.

E. Cross-sectional topic: breast milk–related jaundice + preventing/treating bilirubin overload

Jaundice timing categories (as described)

  • Clears within a few days.
  • Within 24 hours after “orthodontic treatment” (term unclear) → described as a “morbid” cross-section.
  • Persistent beyond 2 weeks → pathological “100-yen coin” transverse lesion (name unclear; persistence is the key point).

Breast milk “cross-conjunctivitis”

  • Explained as physiological: breast milk components cause jaundice/conjunctivitis to subside.
  • Recommendation: usually no need to stop breastfeeding.

Bilirubin overload prevention/treatment principle

  • Excess bilirubin → unbound bilirubin deposits in brain tissue → irreversible once developed.
  • Goal emphasized: prevent bilirubin overload rather than “cure” after damage.

Treatment methodology

  • Phototherapy
    • Converts bilirubin into a form that can be excreted.
    • Effectiveness depends on the type of bilirubin predominance:
      • If indirect bilirubin predominates → phototherapy effective
      • If direct predominates → phototherapy not applicable

  • Mentioned also: exchange transfusion (details unclear in subtitles).

  • Additional references (brief):

    • A condition where stool-related direct changes can be fatal; importance of distinguishing stool color and using a stool color card at home.
    • A “screaming” term likely a subtitle error, suggesting medical evaluation/sampling based on stool color monitoring.

F. Neonatal feeding-related GI condition, gastroenteritis imaging cues, and treatment principle

  • A condition described as common (context garbled) involving:
    • High body fat (50–70% stated), described as dangerous.
    • Symptoms suggesting impaired stomach motility (described as “multiple arrogance,” likely ileus-like/gastric stasis).
  • Imaging cues for gastroenteritis:
    • Start with intramural gas, then intravascular gas.
    • X-ray interpretation should track the progression between these phases.
  • Treatment principle:
    • Internal medicine treatments may be attempted but often don’t help → more specialized treatment needed.

G. Neonatal seizures (“newborn convulsion”)—causes and diagnosis/treatment

Types and presentation

  • Seizures can be subtle in newborns.
  • Tonic/focal seizure-like patterns described (wording garbled).

Causes mentioned

  • Bleeding-related cause (subarachnoid/intracranial hemorrhage concept; garbled).
  • Hypocalcemia (low calcium).
  • Infectious causes referenced.
  • Emphasized metabolic cause: hypoglycemia
  • “Low-calcium crystals” described as a cause of a “new diastema” (likely calcium-related seizure terminology).

Diagnosis

  • “NOH test” mentioned (likely blood glucose/electrolytes; subtitles garbled).
  • Bedside monitoring also stated.

Treatment

  • Priority treatment if an “interatomic agent” is available (term garbled).
  • If seizures continue → add a “synergistic agent” (term garbled).

H. Neonatal nutrition comparisons + vitamin binding diseases

  • Comparison among:
    • Breast milk, “human milk,” and cow’s milk (subtitles treat them similarly, but the key point is comparison).
  • Main difference emphasized:
    • Breast milk contains very little calcium and phosphorus.
  • Milk maturation:
    • Early milk vs mature milk differs in energy, intake, nutrients, protein, and immune substances (as described).
  • Vitamins:
    • Caution about vitamin binding disorders.
    • “Fat-soluble vs water-soluble” concept implied.
    • Diseases may occur depending on how vitamin types are combined/handled (slide list exists; not fully enumerated in subtitles).

I. Growth, development, and prevention levels

  • Growth & development:
    • Textbooks emphasize primitive reflexes and postural reflexes.
    • Key is knowing when reflexes appear and disappear (timing months after birth).
    • Example timing concept: a reflex becomes visible after a few hours (subtitle garbled).
  • Development for special-care children:
    • Domains go beyond gross motor: fine motor, language, social life, etc.
    • Know what a child can do at each age.
  • Prevention framework:
    • Primary, secondary, tertiary prevention.
    • Lecturer emphasizes understanding what each means in each category (mapping not fully provided in subtitles).

J. Vaccinations overview for infants/children

  • Distinguish:
    • Routine (regular) vs individual vaccinations.
  • Vaccine types:
    • Live, inactivated, and COVID-19 mRNA (stated).
  • Routes:
    • Not only injection:
      • BCG external administration mentioned
      • Rotavirus oral route mentioned (subtitle garbled)
      • intramuscular also mentioned
  • Side effects:
    • Lecturer says each vaccine’s characteristic side effects are listed in slides.
  • MR vaccine and autism:
    • Proposed link was disproven.
    • Paper retracted.
    • MR and autism now understood unrelated.

Maternal vaccination for early-life protection

  • Early after birth, routine infant prevention may not be possible yet.
  • Strategy:
    • Vaccinate pregnant women so antibodies transfer to the infant and prevent severe infection.
  • Candidate vaccines mentioned in slides (not enumerated clearly in subtitles).

K. Fever in children: initial triage rules + major infections by season

  • Fever evaluation principle:
    • Most outpatient pediatric fever cases require structured triage.
  • Hospitalization rule:
    • If < 1 month since orthopedic surgery AND temperature ≥38°C → in principle hospitalize.
  • Age risk:
    • Under 1 year, especially under 3 months → urinary tract infection is likely; urine testing needed.
  • Vaccines relevance:
    • Pneumonia and influenza vaccines highlighted.
    • If vaccine timing is missed, similar viruses may still cause illness → blood tests/exams may be needed.
  • Infection ranking:
    • Influenza and pneumonia described as very important; vaccines reduce risk.

L. Selected infectious diseases

Mycoplasma pneumonia

  • Common in school-aged children/young adults.
  • Family spread common.
  • Features:
    • Severe persistent cough
    • Relatively low fever
    • Few other symptoms
    • Imaging shows atypical pneumonia
  • Diagnosis:
    • Ordinary methods may not detect; rapid detection used.
  • Treatment:
    • Macrolides: clarithromycin, azithromycin
    • In older children, additional antibiotics sometimes listed (fluoroquinolones, tetracyclines; some names garbled).

Bacterial infection resembling “British military chain bacterium” (likely meningococcal/streptococcal-like concept; subtitles garbled)

  • Described with a needle-like progressive feature.
  • Differentiation from Kawasaki-like disease mentioned.
  • Complications including cystitis discussed.

HHV-6/7 infection

  • Affects babies 6 months–2 years; often around school entry period.
  • High fever early; rash later after fever described.

Fifth disease (Parvovirus B19)

  • Usually no fever or mild fever at start.
  • Main symptom: rash/tingling.
  • Facial and body rash described.

Adenovirus infections

  • Mentioned as “seal fever / pool fever” etc. (subtitles garbled).
  • Hemorrhagic-prevention/hemorrhagic-like patterns attributed to adenovirus.

Summer contact-transmitted skin infection

  • Outbreaks with contact; name garbled.

“100 Days” disease

  • Long-lasting illness ~3 months.
  • Severe area described as a “mild extracorporeal zone” (unclear wording).
  • Seizures mainly at night (unclear wording).
  • Pertussis-like breath-hold/cyanosis episodes described.
  • Diagnosis considerations:
    • “Bagua blood” count can rise very high (e.g., 15,000 up to 40,000–50,000 mentioned)
    • Lymphocyte predominance described (Lipa class >70%).
  • Treatment:
    • First-line macrolides (erythromycin/clarithromycin etc.; names garbled but macrolides emphasized).
  • Prevention:
    • Routine multi-antigen vaccines mentioned; classified as inactivated vaccine in subtitles.

RSV infection

  • Context unclear, but described as affecting hospitalized children around a “within 6 months of surgery” type of period.
  • Course:
    • Starts with runny nose/redness → worsens.
    • Severe cases may require emergency care, hospitalization, possibly artificial respiration.
  • Prevention:
    • Monoclonal antibody described as limited availability.
    • Not currently a vaccine (emphasized).
    • Pregnant RSV vaccine option previously mentioned as not used “for this time” (timing/availability caveat).

M. Child safety / child abuse / emergency response + metabolic screening + endocrine topics (toward later part)

Causes of death in children

  • Lecturer plans to list the top four causes by age group, emphasizing memorizing the top two per group.

Child abuse

  • Types:
    • Physical, sexual, neglect, emotional
  • Most common described as psychological.
  • Suspicion criteria:
    • Suspect abuse when infection is unlikely to be transmitted mother-to-child and is not transmitted via sexual/other routes.

Emergency medical service approach (ambulance arrival)

  • BLS (Basic Life Support)
    • Primary:
      • Assess responsiveness
      • Gather help
      • Arrange AED if needed
      • Assess breathing/pulse to decide artificial respiration vs compressions
    • Secondary:
      • Pulse palpation
      • Decide shock using a device
  • CPR medication:
    • Adrenaline dose mentioned: 0.01 mg/kg
    • Route/placement described as two possible sites (names garbled; “two routes” concept emphasized).

Metabolic newborn screening (“mass screening”)

  • Goal:
    • Detect congenital metabolic disorders early (amino acid/carbohydrate metabolism and others).
  • Timing:
    • 4–6 days after birth
    • Collect small blood from heel/sole.
  • Methods:
    • Screening tests expanded using a “short-circuit mass” method to cover additional categories including:
      • urea cycle
      • aerobic metabolism
      • fat metabolism
    • (Original tests were for specific metabolic disorders.)

Diabetes and diabetic ketoacidosis (concepts)

  • Type 1 vs Type 2 differentiation.
  • Diabetic foot artery disease mentioned as a complication.
  • Deep breathing compensatory pattern described.
  • Lab concept:
    • Bicarbonate decreases
    • ABG shows characteristic decreased bicarbonate partial pressure.

Congenital adrenal-related malformation category (CAH-type concept)

  • “21-enzyme structural deficiency” described as ~90% of cases.
  • Subtypes mentioned:
    • Salt-losing
    • Simple virilizing
    • Masculinizing types
  • Treatment principle:
    • Steroid replacement (corticoid replacement)
    • Stress dosing with dropwise steroid when needed.
  • Surgery:
    • May be required if masculinization occurs, typically around ages ~2–3 years / around puberty period (subtitle wording garbled).

Short stature and endocrine syndromes

  • Short stature definition:
    • Height below -2 SD of standard height.
  • Turner syndrome:
    • XO causes delayed/slow height growth (not small at birth; slows later).
    • Treatment: growth hormone + additional hormone replacement (estrogen/related).
    • Manage LH/FSH via feedback concept (as described).
  • Klinefelter syndrome:
    • XXY; described as tall rather than dwarfism
    • Delayed secondary sexual characteristics.
  • Tanner classification:
    • Staging secondary sexual development for both sexes.

Obesity

  • Emphasis:
    • Beyond simple obesity, consider hereditary and endocrine causes.
  • Example:
    • Prader-Willi syndrome as hereditary obesity with characteristic physical findings.

Speakers / sources featured

  • Speaker: Iijima (pediatrician; lecturer for the course)

Original video